Renate Kirschner-Schwabe, Claudio Lottaz, Jörn Tödling, Peter Rhein, Leonid Karawajew, Cornelia Eckert, Arend von Stackelberg, Ute Ungethüm, Dennis Kostka, Andreas E Kulozik, Wolf-Dieter Ludwig, Günter Henze, Rainer Spang, Christian Hagemeier, Karl Seeger
PURPOSE: In childhood acute lymphoblastic leukemia (ALL), approximately 25% of patients suffer from relapse. In recurrent disease, despite intensified therapy, overall cure rates of 40% remain unsatisfactory and survival rates are particularly poor in certain subgroups. The probability of long-term survival after relapse is predicted from well-established prognostic factors (i.e., time and site of relapse, immunophenotype, and minimal residual disease). However, the underlying biological determinants of these prognostic factors remain poorly understood...
August 1, 2006: Clinical Cancer Research